These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17689998)

  • 21. Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease.
    Mills K; Vellodi A; Morris P; Cooper D; Morris M; Young E; Winchester B
    Eur J Pediatr; 2004 Oct; 163(10):595-603. PubMed ID: 15243806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?
    Hollak CE; Linthorst GE
    Mol Genet Metab; 2009 Jan; 96(1):1-3. PubMed ID: 19062323
    [No Abstract]   [Full Text] [Related]  

  • 23. Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents.
    Ries M; Clarke JT; Whybra C; Mehta A; Loveday KS; Brady RO; Beck M; Schiffmann R
    J Clin Pharmacol; 2007 Oct; 47(10):1222-30. PubMed ID: 17698592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.
    van Breemen MJ; Rombach SM; Dekker N; Poorthuis BJ; Linthorst GE; Zwinderman AH; Breunig F; Wanner C; Aerts JM; Hollak CE
    Biochim Biophys Acta; 2011 Jan; 1812(1):70-6. PubMed ID: 20851180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.
    Pastores GM; Boyd E; Crandall K; Whelan A; Piersall L; Barnett N
    Nephrol Dial Transplant; 2007 Jul; 22(7):1920-5. PubMed ID: 17395657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease.
    Schiffmann R; Martin RA; Reimschisel T; Johnson K; Castaneda V; Lien YH; Pastores GM; Kampmann C; Ries M; Clarke JT
    J Pediatr; 2010 May; 156(5):832-7, 837.e1. PubMed ID: 20097359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with agalsidase beta during pregnancy in Fabry disease.
    Politei JM
    J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease.
    Ramaswami U; Wendt S; Pintos-Morell G; Parini R; Whybra C; Leon Leal JA; Santus F; Beck M
    Acta Paediatr; 2007 Jan; 96(1):122-7. PubMed ID: 17187618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Agalsidase benefits renal histology in young patients with Fabry disease.
    Tøndel C; Bostad L; Larsen KK; Hirth A; Vikse BE; Houge G; Svarstad E
    J Am Soc Nephrol; 2013 Jan; 24(1):137-48. PubMed ID: 23274955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.
    Mignani R; Panichi V; Giudicissi A; Taccola D; Boscaro F; Feletti C; Moneti G; Cagnoli L
    Kidney Int; 2004 Apr; 65(4):1381-5. PubMed ID: 15086478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surges in proteinuria are associated with plasma GL-3 elevations in a young patient with classic Fabry disease.
    Kanai T; Ito T; Odaka J; Saito T; Aoyagi J; Betsui H; Yamagata T
    Eur J Pediatr; 2016 Mar; 175(3):427-31. PubMed ID: 26454753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Contribution of the measurement of globotriaosylceramide in urine to the diagnosis and follow-up of Fabry disease].
    Piraud M; Maire I; Froissart R
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S270-4. PubMed ID: 21211678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.
    Mehta A; Beck M; Kampmann C; Frustaci A; Germain DP; Pastores GM; Sunder-Plassmann G
    Mol Genet Metab; 2008; 95(1-2):114-5. PubMed ID: 18701330
    [No Abstract]   [Full Text] [Related]  

  • 34. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.
    Wilcox WR; Banikazemi M; Guffon N; Waldek S; Lee P; Linthorst GE; Desnick RJ; Germain DP;
    Am J Hum Genet; 2004 Jul; 75(1):65-74. PubMed ID: 15154115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diagnosis of Fabry disease: usefulness of the clinical investigation].
    Demontis R
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S229-32. PubMed ID: 21211670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibodies against recombinant alpha-galactosidase A in Fabry disease: Subclass analysis and impact on response to treatment.
    van der Veen SJ; van Kuilenburg ABP; Hollak CEM; Kaijen PHP; Voorberg J; Langeveld M
    Mol Genet Metab; 2019 Feb; 126(2):162-168. PubMed ID: 30473480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.
    Ries M; Clarke JT; Whybra C; Timmons M; Robinson C; Schlaggar BL; Pastores G; Lien YH; Kampmann C; Brady RO; Beck M; Schiffmann R
    Pediatrics; 2006 Sep; 118(3):924-32. PubMed ID: 16950982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease.
    van der Veen SJ; Vlietstra WJ; van Dussen L; van Kuilenburg ABP; Dijkgraaf MGW; Lenders M; Brand E; Wanner C; Hughes D; Elliott PM; Hollak CEM; Langeveld M
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32806627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful desensitization to agalsidase beta after anaphylaxis.
    Talreja N; Butt A; Valle RL; Fox RW; Lockey RF
    Ann Allergy Asthma Immunol; 2014 Jan; 112(1):71-2. PubMed ID: 24331397
    [No Abstract]   [Full Text] [Related]  

  • 40. Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients.
    Skrunes R; Svarstad E; Kampevold Larsen K; Leh S; Tøndel C
    Nephrol Dial Transplant; 2017 May; 32(5):807-813. PubMed ID: 27190352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.